Baidu
map

急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议

2018-04-30 中国医师协会心血管内科医师分会 中华心血管病杂志,2018,46(4) :255-266.

抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会

中文标题:

急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议

发布日期:

2018-04-30

简要介绍:

抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会、中华医学会心血管病学分会介入心脏病学组、中华心血管病杂志编辑委员会发起,根据近年国内外冠心病特殊人群抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验,制定此建议。本建议主要涉及高龄、溶栓治疗、合用口服抗凝药、肺栓塞(或静脉血栓栓塞症)、脑血管疾病、近期消化道出血病史、糖尿病、肾功能不全、痛风或高尿酸、缺铁性贫血、血小板计数低、冠状动脉旁路移植术(coronary artery bypass grafting, CABG)及非心脏外科手术围术期等12类特殊人群的抗血小板治疗。希望通过本建议的制定与应用,为优化临床特殊人群抗血小板治疗提供指导。 

拓展指南:抗血小板相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议)] GetToolGuiderByIdResponse(projectId=1, id=13c171c001591ad7, title=急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议, enTitle=, guiderFrom=中华心血管病杂志,2018,46(4) :255-266., authorId=null, author=, summary=抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会, cover=, journalId=null, articlesId=null, associationId=315, associationName=中国医师协会心血管内科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Apr 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会、中华医学会心血管病学分会介入心脏病学组、中华心血管病杂志编辑委员会发起,根据近年国内外冠心病特殊人群抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验,制定此建议。本建议主要涉及高龄、溶栓治疗、合用口服抗凝药、肺栓塞(或静脉血栓栓塞症)、脑血管疾病、近期消化道出血病史、糖尿病、肾功能不全、痛风或高尿酸、缺铁性贫血、血小板计数低、冠状动脉旁路移植术(coronary artery bypass grafting, CABG)及非心脏外科手术围术期等12类特殊人群的抗血小板治疗。希望通过本建议的制定与应用,为优化临床特殊人群抗血小板治疗提供指导。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>抗血小板</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=098ce1c0015a03f5" title="2018 CCS/CAIC指南:抗血小板治疗的应用(更新版)" target=_blank>2018 CCS/CAIC指南:抗血小板治疗的应用(更新版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=12c2e1c00153e8c3" title="2017 ASRA/ESRA/AAPM/INS/NANS/WIP指南:服用抗血小板和抗凝药物患者进行脊柱和疼痛介入治疗(第2版)" target=_blank>2017 ASRA/ESRA/AAPM/INS/NANS/WIP指南:服用抗血小板和抗凝药物患者进行脊柱和疼痛介入治疗(第2版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=7cb011c0013e37c8" title="2016 BCSH指南:抗凝和抗血小板治疗围术期管理" target=_blank>2016 BCSH指南:抗凝和抗血小板治疗围术期管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f2d511c00133211f" title="缺血性脑卒中患者围手术期抗血小板药物应用中国专家共识2016" target=_blank>缺血性脑卒中患者围手术期抗血小板药物应用中国专家共识2016</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=c01ca1c0012e19c1" title="2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识" target=_blank>2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E6%8A%97%E8%A1%80%E5%B0%8F%E6%9D%BF" target=_blank>有关抗血小板更多指南</a></ul>, tagList=[TagDto(tagId=3430, tagName=急性冠状动脉综合征), TagDto(tagId=33717, tagName=特殊人群), TagDto(tagId=2733, tagName=抗血小板治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13096, appHits=963, showAppHits=18, pcHits=7970, showPcHits=5323, likes=159, shares=67, comments=3, approvalStatus=1, publishedTime=Mon May 14 21:58:17 CST 2018, publishedTimeString=2018-04-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon May 14 21:58:17 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 01:36:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议)])
急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=315544, encodeId=0d713155444c, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 16 06:19:29 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315395, encodeId=383f315395ba, content=学习一下很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue May 15 19:00:23 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315118, encodeId=0d85315118a6, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Mon May 14 22:14:40 CST 2018, time=2018-05-14, status=1, ipAttribution=)]
    2018-05-16 大爰

    学习了谢谢分享!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=315544, encodeId=0d713155444c, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 16 06:19:29 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315395, encodeId=383f315395ba, content=学习一下很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue May 15 19:00:23 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315118, encodeId=0d85315118a6, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Mon May 14 22:14:40 CST 2018, time=2018-05-14, status=1, ipAttribution=)]
    2018-05-15 虈亣靌

    学习一下很不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=315544, encodeId=0d713155444c, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 16 06:19:29 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315395, encodeId=383f315395ba, content=学习一下很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue May 15 19:00:23 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315118, encodeId=0d85315118a6, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Mon May 14 22:14:40 CST 2018, time=2018-05-14, status=1, ipAttribution=)]
    2018-05-14 wqkm

    ^_^^_^^_^

    0

Baidu
map
Baidu
map
Baidu
map